I obtained my BSc in Biomedical Sciences, in 2021, with a final grade of 15/20. In my last year I produced my first research study entitled: “Estudo do papel do componente dos grânulos de stress CARHSP1 nas doenças de poliglutaminas”. In 2023, I completed my MSc in Biomedical Sciences-disease mechanisms, obtaining a grade of 18/20. Throughout my master’s thesis, I established a novel Cockayne syndrome B neuronal culture model using induced pluripotent stem cells derived from patients, where I obtained a grade of 19/20. This endeavor aimed to draw parallels with the human condition, facilitating the translation of promising outcomes into clinical testing for new therapeutic approaches. In the end of 2023, I transitioned into a role as a research fellow at the Molecular Neuroscience and Gene Therapy (MNGT) Laboratory, under the guidance of Professor Clévio Nóbrega at the Algarve Biomedical Center Research Institute (ABC-RI), University of Algarve. Currently, I'm pursuing a PhD at the University of Algarve, where my PhD project focuses on employing a CRISPR/Cas-based tool as a potential therapeutic approach for Spinocerebellar Ataxia type 2 (SCA2). Throughout my research activities I have gained proficiency in a diverse array of techniques, including fibroblast reprogramming into induced pluripotent stem cells, cell culture, molecular cloning, Western blot analysis, lentiviral vectors, immunocytochemistry, PCR, immunohistochemistry, analysis of animal slices, and statistical analysis. Until now, I have co-authored a journal article titled "Insights Into Cockayne Syndrome Type B: What Underlies Its Pathogenesis?" published in the Q1 journal Aging Cell (2025). Furthermore, I have been selected for several poster presentations at international meetings: European Neuroscience Conference by Doctoral Students (ENCONDS) (2023), Federation of European Neuroscience Societies (FENS) Regional Meeting (FRM) (2023), International congress for ataxia research (ICAR) (2024), Congresso da sociedade portuguesa de neurociências (SPN) (2025) and European Society of Gene and Cell Therapy (ESGCT) (2025). I was also selected for an oral presentation at 54º Meeting da Sociedade Portuguesa de Farmacologia (SPF) (2024).